Axitinib for metastatic non-clear cell renal cell carcinoma
Results from a phase 2 clinical trial of axitinib (Inlyta) [...]
An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma
The International Kidney Cancer Coalition (IKCC), of which KCSN is [...]
Avelumab plus axitinib combination effective in the first-line but with unfavourable side effects
Safety results from a phase 1b dose-finding and dose expansion [...]
Implications of real world data on the use of first-line pazopanib for the management of metastatic kidney cancer
The following interview with Dr Eric Jonasch, medical oncologist from MD Anderson Cancer Centre [...]
Treatment of metastatic kidney cancer in older patients
A recent meta-analysis evaluating the efficacy of first- and second-line [...]
Immunotherapy for non-clear cell kidney cancer
The following interview with Dr Eric Jonasch, medical oncologist from [...]
Patient-reported outcomes for atezolizumab plus bevacizumab combination
Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed [...]
Pembrolizumab shows promise as first-line treatment for advanced kidney cancer
The immune checkpoint (PD-1) inhibitor, pembrolizumab, shows promise as a [...]
Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer
The results from the renal cell carcinoma (RCC) group of [...]
NICE set to decline first-line cabozantinib for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) have issued an [...]
